✦ LIBER ✦

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505)

✍ Scribed by Chouaid, Christos; Le Caer, Hervé; Corre, Romain; Crequit, Jacquy; Locher, Chrystelle; Falchero, Lionel; Dujon, Cecile; Berard, Henri; Monnet, Isabelle; Vergnenegre, Alain

Book ID: 123441414
Publisher: CIG Media Group, LP.
Year: 2013
Tongue: English
Weight: 781 KB
Volume: 14
Category: Article
ISSN: 1525-7304
DOI: 10.1016/j.cllc.2012.04.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost effectivenes of erlotinib versus ch

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

✍ Chouaid Christos, Le Caer Hervé, Locher Chrystelle, Dujon Cecile, Thomas Pascal, 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 569 KB

PCN79 Cost Effectiveness of Erlotinib in

PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients: An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)

✍ Chouaid, C.; Le Caer, H.; Corre, R.; Crequit, J.; Jullian, H.; Falchero, L.; Duj 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN

PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504)

✍ C Chouaid; H Lecaer; J Crequit; I Monnet; S Chouabe; C Locher; D Paillotin; JB A 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

A phase II study of erlotinib in combina

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer

✍ Ciuleanu, T.; Tsai, C.-M.; Tsao, C.-J.; Milanowski, J.; Amoroso, D.; Heo, D.S.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 718 KB

Randomized open-label non-comparative mu

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study

✍ Auliac, J.B.; Chouaid, C.; Greiller, L.; Monnet, I.; Le Caer, H.; Falchero, L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 484 KB

PCN90 Cost-Effectiveness Analysis of Erl

PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB